CD34+selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure.

The article focuses on a study which states that CD34+ selected haematopoietic stem cell (HSC), not preceded by any immunosuppressive therapy, offer an effective treatment for graft failure. The researchers here report a case of graft failure occurring after a T-cell replete allogeneic HSC transplantation that was successfully treated using an infusion of CD34+ immuno-selected HSC without any prior immunosuppression. It was concluded that graft dysfunction may be the result of microenvironment abnormalities pre-existing the transplant or of toxic effects toward HSC from viral infections or drugs. Graft dysfunction may also be due to an immunological reaction.